Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Catalyst licenses North American rights to BioMarin's LEMS candidate Firdapse; Japan rights added

Executive Summary

BioMarin Pharmaceutical Inc. (developing treatments for rare diseases) has granted specialty pharmaco Catalyst Pharmaceutical Partners Inc. exclusive rights to develop and sell the autoimmune disease therapy Firdapse (amifampridine) in North America.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register